4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
OSE Immunotherapeutics SA (OSE) operates in the Biotechnology industry and is headquartered in Nantes, France with about 64 employees. Its market capitalization is roughly €79 million. In the fiscal year ended 2025-12-31, OSE reported €3M in revenue and (€38M) in net income.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €3M | €70M | €2M | €18M | — |
| Operating Income (EBIT) | (€37M) | €44M | (€23M) | (€18M) | — |
| Net Income | (€38M) | €37M | (€23M) | (€18M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €79M | €124M | €82M | €92M | — |
| Total Liabilities | €51M | €60M | €59M | €59M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OSE viewer.
About TickerBase · Data methodology & sources · Privacy · Terms